Loading asset research
Aldeyra Therapeutics Inc. Common Stock
ALDXNasdaq · USD · StocksQuote as of · Exchange session not verified$1.34
-8.22%
Today
ALDX
Loading 1D prices…
Market cap
$80.8M
Volume
1.6M
52w high
$5.9352w low
$1.07Company profile
Aldeyra Therapeutics Inc. Common Stock
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Lexington, MA, United States
Employees
6
Fiscal year end
1231
CIK
1341235
Session & valuation
Open$1.48
Previous close$1.46
Day high$1.48
Day low$1.33
30-day avg. volume735.6K
Outstanding shares60.3M
Diluted EPS-$0.56
Latest annual period
P/E (trailing)-2.39
P/E (forward)-4.87
Price / book2.13
Beta1.19
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| TELOTelomir Pharmaceuticals Inc. Common Stock | $80.5M | $0.00 | — | -$0.33 | -0.85% | Unrated |
| RNXTRenovoRx Inc. Common Stock | $79.4M | $1.1M | -994.48% | -$0.32 | -0.56% | Buy |
| MAIAMAIA Biotechnology Inc. Common Stock | $79.1M | $0.00 | — | -$0.70 | -1.53% | Buy |
| OSTXOS Therapies Incorporated Common Stock | $78.6M | $0.00 | — | -$0.98 | -7.69% | Buy |
| FBIOFortress Biotech Inc. Common Stock | $84M | $63.3M | +58.49% | -$0.07 | -1.95% | Buy |